169 related articles for article (PubMed ID: 29370721)
1. Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.
Ziffels B; Pretto F; Neri D
Immunotherapy; 2018 Mar; 10(3):177-188. PubMed ID: 29370721
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
4. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
Schwager K; Hemmerle T; Aebischer D; Neri D
J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.
Ye L; Fan J; Shi X; Tao Q; Ye D; Xian Z; Zeng X; Li Y; Feng M; Ju D
Appl Microbiol Biotechnol; 2014 May; 98(9):4053-61. PubMed ID: 24276620
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Ziffels B; Stringhini M; Probst P; Fugmann T; Sturm T; Neri D
Mol Cancer Ther; 2019 Sep; 18(9):1544-1554. PubMed ID: 31213507
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy.
Christ O; Seiter S; Matzku S; Burger C; Zöller M
Clin Cancer Res; 2001 Apr; 7(4):985-98. PubMed ID: 11309350
[TBL] [Abstract][Full Text] [Related]
12. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
De Luca R; Soltermann A; Pretto F; Pemberton-Ross C; Pellegrini G; Wulhfard S; Neri D
Mol Cancer Ther; 2017 Nov; 16(11):2442-2451. PubMed ID: 28716814
[TBL] [Abstract][Full Text] [Related]
13. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D
J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045
[TBL] [Abstract][Full Text] [Related]
14. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.
Schliemann C; Palumbo A; Zuberbühler K; Villa A; Kaspar M; Trachsel E; Klapper W; Menssen HD; Neri D
Blood; 2009 Mar; 113(10):2275-83. PubMed ID: 19005180
[TBL] [Abstract][Full Text] [Related]
15. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
16. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
17. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
18. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
Danielli R; Patuzzo R; Di Giacomo AM; Gallino G; Maurichi A; Di Florio A; Cutaia O; Lazzeri A; Fazio C; Miracco C; Giovannoni L; Elia G; Neri D; Maio M; Santinami M
Cancer Immunol Immunother; 2015 Aug; 64(8):999-1009. PubMed ID: 25971540
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.
Moschetta M; Pretto F; Berndt A; Galler K; Richter P; Bassi A; Oliva P; Micotti E; Valbusa G; Schwager K; Kaspar M; Trachsel E; Kosmehl H; Bani MR; Neri D; Giavazzi R
Cancer Res; 2012 Apr; 72(7):1814-24. PubMed ID: 22392081
[TBL] [Abstract][Full Text] [Related]
20. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
